Siponimod shows promise through 24 months in relapsing-remitting MS

Once-daily oral siponimod was associated with sustained effects on MRI outcomes at 24 months in patients with relapsing-remitting multiple sclerosis in a dose-blinded extension of the phase II...
Source: Family Practice News - Category: Primary Care Source Type: news